Scilex Holding Company Addresses Product Composition Questions for ELYXYB Patent in Canada, While Preparing for the Launch of Gloperba and Expanding Its Distribution Network
PALO ALTO, Calif. March 18, 2024 Scilex Holding Company (Nasdaq: SCLX), a revenue-generating company focused on non-opioid pain management products, has provided responses to Health Canada’s Office of Patented Medicines and Liaison (OPML) regarding the product composition of its ELYXYB patent. The submission is currently under review by Health Canada for the approval of ELYXYB for the acute treatment of migraine with or without aura in Canada.
Scilex Holding Company, based in Palo Alto, California, specializes in acquiring, developing, and commercializing innovative pain management solutions for both acute and chronic pain conditions. Their commitment to providing effective alternatives to opioids has positioned them as a leader in the industry.
The company’s response to Health Canada’s questions on the product composition of ELYXYB highlights its dedication to transparency and complete adherence to regulatory requirements. This pivotal step brings them closer to the approval of ELYXYB for migraine treatment, addressing a significant unmet medical need in Canada.
In addition to their progress with ELYXYB, Scilex Holding Company has also set plans for the launch of Gloperba, their first and only liquid oral version of the anti-gout medicine colchicine. The launch is expected to take place in the first half of 2024, with a retail price of $595 per 150ml bottle.
Gloperba, an FDA-approved liquid formulation of colchicine, offers a prophylactic treatment for acute gout flares. This formulation provides healthcare providers the ability to administer precise doses to patients with chronic kidney disease or gastrointestinal sensitivity. By offering lower doses than the standard tablet or capsule, Gloperba helps mitigate the risk of severe toxicity in vulnerable patient populations.
Scilex Holding Company’s collaboration with a leading national pharmacy chain to stock Gloperba in most of their stores throughout the U.S. further demonstrates their commitment to making innovative pain management options accessible to a wide range of patients. This strategic partnership aims to ensure that Gloperba is readily available to those in need, once it launches in the U.S. in the first half of 2024.
The decision to expand manufacturing capabilities for Gloperba is a direct response to the anticipated demand and increased stocking needs in distribution centers. This move highlights Scilex Holding Company’s foresight in aligning production capacity with potential market requirements.
As Scilex Holding Company continues to make significant strides in pain management innovation, their commitment to improving patient outcomes remains steadfast. The approval process for ELYXYB in Canada and the forthcoming launch of Gloperba in the U.S. mark significant milestones in their mission to provide safer and more effective alternatives to opioid-based pain management.
Comments